Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is attracting investor attention: Here is what you should know
Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
Pfizer PFE stock has been trading above its 50-day moving average since early November, indicating a potential short-term bullish trend. The 50-day SMA is a key indicator for traders and analysts, ...
Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback